On the other hand, due to the temporal and spatial heterogeneity, the level of PD-L1 shown by lung biopsy immunohistochemistry may not be the true level of cancer patients, so NSCLC patients with negative PD-L1 expression may also benefit significantly from immunotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.